免疫检查点抑制剂一线治疗晚期NSCLC的现状与展望

With the breakthroughs achieved of programmed death-1 (PD-1)/PD-L1 inhibitors monotherapy as first-line and second-line treatment in advanced non-small cell lung cancer (NSCLC), the treatment strategy is gradually evolving and optimizing. Immune combination therapy expands the benefit population and...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2017
Materias:
综述
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973355/
https://www.ncbi.nlm.nih.gov/pubmed/28641702
http://dx.doi.org/10.3779/j.issn.1009-3419.2017.06.10
_version_ 1783326607056830464
collection PubMed
description With the breakthroughs achieved of programmed death-1 (PD-1)/PD-L1 inhibitors monotherapy as first-line and second-line treatment in advanced non-small cell lung cancer (NSCLC), the treatment strategy is gradually evolving and optimizing. Immune combination therapy expands the benefit population and improves the curative effect. A series of randomized phase Ⅲ trials are ongoing. In this review, we discuss the prospect and current situation of immune checkpoint inhibitors in first-line treatment in advanced NSCLC patients.
format Online
Article
Text
id pubmed-5973355
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-59733552018-07-06 免疫检查点抑制剂一线治疗晚期NSCLC的现状与展望 Zhongguo Fei Ai Za Zhi 综述 With the breakthroughs achieved of programmed death-1 (PD-1)/PD-L1 inhibitors monotherapy as first-line and second-line treatment in advanced non-small cell lung cancer (NSCLC), the treatment strategy is gradually evolving and optimizing. Immune combination therapy expands the benefit population and improves the curative effect. A series of randomized phase Ⅲ trials are ongoing. In this review, we discuss the prospect and current situation of immune checkpoint inhibitors in first-line treatment in advanced NSCLC patients. 中国肺癌杂志编辑部 2017-06-20 /pmc/articles/PMC5973355/ /pubmed/28641702 http://dx.doi.org/10.3779/j.issn.1009-3419.2017.06.10 Text en 版权所有©《中国肺癌杂志》编辑部2017 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 综述
免疫检查点抑制剂一线治疗晚期NSCLC的现状与展望
title 免疫检查点抑制剂一线治疗晚期NSCLC的现状与展望
title_full 免疫检查点抑制剂一线治疗晚期NSCLC的现状与展望
title_fullStr 免疫检查点抑制剂一线治疗晚期NSCLC的现状与展望
title_full_unstemmed 免疫检查点抑制剂一线治疗晚期NSCLC的现状与展望
title_short 免疫检查点抑制剂一线治疗晚期NSCLC的现状与展望
title_sort 免疫检查点抑制剂一线治疗晚期nsclc的现状与展望
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973355/
https://www.ncbi.nlm.nih.gov/pubmed/28641702
http://dx.doi.org/10.3779/j.issn.1009-3419.2017.06.10
work_keys_str_mv AT miǎnyìjiǎnchádiǎnyìzhìjìyīxiànzhìliáowǎnqīnsclcdexiànzhuàngyǔzhǎnwàng

Ejemplares similares